Pembrolizumab
Phase 2RecruitingInterest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Extranodal NK-T-Cell
Conditions
Lymphoma, Extranodal NK-T-Cell
Trial Timeline
Feb 11, 2022 → Dec 1, 2026
NCT ID
NCT04417166About Pembrolizumab
Pembrolizumab is a phase 2 stage product being developed by Merck for Lymphoma, Extranodal NK-T-Cell. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04417166. Target conditions include Lymphoma, Extranodal NK-T-Cell.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Extranodal NK-T-Cell were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02083484 | Pre-clinical | Completed |
| NCT07302347 | Phase 1/2 | Recruiting |
| NCT07089992 | Phase 2 | Recruiting |
| NCT07007273 | Phase 2 | Recruiting |
| NCT04569461 | Phase 2 | Withdrawn |
| NCT05815927 | Phase 3 | Recruiting |
| NCT05852223 | Phase 2 | Recruiting |
| NCT05879120 | Phase 2 | Withdrawn |
| NCT06004336 | Phase 2 | Recruiting |
| NCT05496036 | Phase 2 | Recruiting |
| NCT05131919 | Phase 2 | Active |
| NCT05197322 | Phase 2 | Recruiting |
| NCT05406713 | Phase 2 | Active |
| NCT05025813 | Phase 2 | Recruiting |
| NCT06413095 | Phase 1 | Completed |
| NCT05191472 | Phase 2 | Terminated |
| NCT05204160 | Phase 2 | Withdrawn |
| NCT04575961 | Phase 2 | Active |
| NCT04417166 | Phase 2 | Recruiting |
| NCT05188508 | Phase 2 | Recruiting |
Competing Products
20 competing products in Lymphoma, Extranodal NK-T-Cell